一线化疗联合分子靶向治疗乳腺癌患者的效果及对束蛋白结合蛋白1、17β-羟基类固醇脱氢酶表达水平的影响

Effect of first-line chemotherapy combined with molecular medicine targeted therapy in breast cancer patients and its impact on the expression levels of fascin actin-binding protein 1 and 17β-hydroxysteroid dehydrogenase

目的探究应用一线化疗联合分子靶向治疗乳腺癌患者的效果及对束蛋白结合蛋白1(FSCN1)、17β-羟基类固醇脱氢酶(17β-HSD)表达水平的影响。方法将152例乳腺癌患者根据不同的治疗方案分为一线化疗组和联合干预组,每组76例,一线化疗组患者仅使用一线化疗治疗,联合干预组在一线化疗组基础上联合分子靶向治疗。比较两组患者应激反应指标水平[一氧化氮(NO)、超氧化物歧化酶(SOD)及血清皮质醇(Cor)]、血管新生指标水平[血管内皮生长因子(VEGF)A、B]、生活质量评分、FSCN1及17β-HSD阳性情况、不良反应发生情况。结果治疗后,联合干预组NO、Cor水平明显低于一线化疗组患者,SOD水平明显高于一线化疗组患者,VEGFA、VEGFB水平均明显低于一线化疗组患者,生活质量各维度评分均明显高于一线化疗组患者,FSCN1、17β-HSD阳性率均明显低于一线化疗组患者,不良反应总发生率明显低于一线化疗组患者,差异均有统计学意义(P﹤0.01)。结论在乳腺癌患者中使用一线化疗联合分子靶向治疗,可改善机体的应激情况,有效抑制肿瘤血管的新生,控制肿瘤细胞的生长及转移能力,提高患者的生活质量,增强患者的信心,对乳腺癌患者有良好的治疗效果。

Objective To investigate the effect of first-line chemotherapy combined with molecular medicine targeted therapy in breast cancer patients and its impact on the expression of fascin actin-binding protein 1(FSCN1)and 17β-hy-droxysteroid dehydrogenase(17β-HSD).Method A total of 152 breast cancer patients were divided into the first-line chemotherapy group and combined group according to varying treatment options,with 76 cases in each group.Patients in the first-line chemotherapy group were received single first-line chemotherapy,and the combined group was combined with molecular medicine targeted based on the first-line chemotherapy group.The levels of stress response indicators[ni-tric oxide(NO),superoxide dismutase(SOD)and serum cortisol(Cor)],angiogenesis indicators[vascular endothelial growth factor(VEGF)A,B],quality of lifescores,FSCN1 and 17β-HSD positive rate,and adverse events were compared between the two groups of patients.Result After the treatment,the levels of NO and Cor in the combined group were significantly lower than those in the first-line chemotherapy group,while the levels of SOD were significantly higher than those in the first-line chemotherapy group;the levels of VEGFA and VEGFB in the combined group were significantly lower than those in the first-line chemotherapy group;the scores of all dimensions of the quality of life were significantly higher than those of the first-line chemotherapy group;the positive rates of FSCN1 and 17β-HSD were lower than those of the first-line chemotherapy group,and the total incidence of adverse events was significantly lower than that of the first-line chemotherapy group,the differences were statistically significant(P<0.01).Conclusion The application of first-line chemotherapy combined with molecular medicine targeted therapy in breast cancer patients could relieve the general stress,effectively inhibit tumor angiogenesis,and control the growth and metastasis of cancer cells.This method could finally improve patients’life quality and enhance their confidence,which could bring satisfactory therapeutic bene-fits to these people.